கிட்நீ புற்றுநோய் ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கிட்நீ புற்றுநோய் ப்ரோக்ர்யாம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கிட்நீ புற்றுநோய் ப்ரோக்ர்யாம் Today - Breaking & Trending Today

Singer, clinical leader at Rutgers Cancer Institute, recognized as ASCO fellow


Dr. Eric Singer, Rutgers Cancer Institute of New Jersey associate chief of urology and urologic oncology and director of the Kidney Cancer Program, has been named a fellow of the American Society of Clinical Oncology.
This distinction honors members for their extraordinary volunteer service and dedication to the American Society of Clinical Oncology.
Singer, an expert in the management of kidney cancer, has been a member of ASCO since 2003 and has served on the ethics committee, clinical practice guidelines committee, annual meeting education committee and twice as a guideline chair. Singer works closely with his medical oncology and radiation oncology colleagues to offer patients an individualized and comprehensive cancer treatment plan that minimizes side effects and maximizes quality of life. ....

United States , Rutgers University , New Jersey , Steve Libutti , Eric Singer , Rutgers Robert Wood Johnson Medical School , American Society Of Clinical Oncology , Rutgers Cancer Institute Of New Jersey , National Institutes Of Health , University Of Rochester Medical Center , National Cancer Comprehensive Center , Rwjbarnabas Health , Harvard Th Chan School Of Public Health , Georgetown University , Kidney Cancer Program , Rutgers Cancer Institute , American Society , Urologic Oncology Branch , National Cancer , Rochester Medical Center , National Institutes , Public Health , ஒன்றுபட்டது மாநிலங்களில் , ரட்ஜர்ஸ் பல்கலைக்கழகம் , புதியது ஜெர்சி , எரிக் பாடகர் ,

Exelixis Highlights Positive Results for CABOMETYX (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU


® (cabozantinib) compared with sunitinib, the current preferred therapy according to U.S. cancer treatment guidelines,
1 in patients with metastatic papillary renal cell carcinoma (PRCC), a form of kidney cancer. The data from the S1500 trial (also called “PAPMET”), which was designed and managed by SWOG Cancer Research Network, will be presented on Saturday, February 13
th during the Oral Abstract Session: Renal Cell Cancer at 10:00 – 11:15 a.m. PT at the 2021 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU), which is being held virtually, February 11-13, 2021. The findings will be simultaneously published in
The Lancet.
“This is the first randomized trial specific to metastatic papillary renal cell carcinoma to show a clinically and statistically significant benefit with a targeted therapy, CABOMETYX, over an existing standard of care,” said Dr. Sumanta Pal, Clinical Professor and Co-Director of the Kidney Cancer Pro ....

United States , Susan Hubbard , Sumanta Pal , Lindsay Treadway , John Wright , Gisela Schwab , National Cancer Institute , Cancer Therapy Evaluation Program , Takeda Pharmaceutical Company , Product Development , Exelixis Inc , Kidney Cancer Program , Public Affairs , Cancer Research Network , Cancer Genome Atlas Research Network , European Union , American Cancer Society , Development Agreement , National Clinical Trials Network , Investigational Drug Branch , National Institutes Of Health , Exchange Commission , Research Network , Oral Abstract Session , Renal Cell Cancer , Clinical Oncology ,